PRAXIS PRECISION MED (PRAX) is drawing unusual attention today. Our newswire has captured 3 stories on PRAX across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100).
Praxis Precision Medicines (PRAX) shares surged 20.03% to close at $332.97. The primary driver was the company’s third-quarter 2026 financial results, which included a non-GAAP EPS beat and a substantial cash reserve that extends operational runway into 2028.
Praxis Precision Medicines reported third-quarter 2026 financial results via an SEC Form 8-K filed on November 9, 2026. The company posted a non-GAAP EPS of -$3.23, which beat the consensus estimate of -$3.66 by $0.40. Management highlighted that cash and investments totaled approximately $1.3 billion as of September 30, 2026, providing funding for operations into 2028. The company also provided updates on its pipeline, noting that FDA reviews are ongoing for relutrigine with a PDUFA target action date of December 27, 2026, and ulixacaltamide HCI with a target action date of January 29, 2027.
Following the release, BTIG reaffirmed its "Buy" rating and maintained a price target of $826. Raymond James reiterated its "Strong Buy" rating on the stock. Wedbush also adjusted its price target for the company.
The stock’s market capitalization stands at $7.8 billion. The company remains unprofitable with a trailing twelve-month EPS of -$12.86, though revenue has grown 365.0% over the same period. The stock carries a beta of 2.84 and has traded within a 52-week range of $159.74 to $392.70. In the eight sessions leading up to the move, the stock gained 7.8%, rising from $264.49 to $285.06. On November 9, 2026, the stock printed 34 fresh 52-week highs and 4 fresh 52-week lows.
Recent congressional disclosures show four buys and zero sells in the last 90 days, with the most recent filing on October 12, 2026. Representative Gilbert Ray Cisneros, Jr. disclosed purchases of $1,001 to $15,000 on September 29, 2026, and July 30, 2026.
Investors will monitor the FDA review processes for relutrigine and ulixacaltamide HCI, with target action dates set for late 2026 and early 2027, respectively.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Filed: 2026-11-12 AccNo: 0001689548-26-000091 Size: 20 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027 Shared...
Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027 Shared updated...
PRAXIS PRECISION MED (PRAX) is drawing unusual attention today. Our newswire has captured 3 stories on PRAX across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100). The most recent driver: "Praxis Precision Medicines, Inc. (PRAX) files 8-K: Items 7.01, 8.01, 9.01" (SEC 8-K).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of PRAX coverage reads 59/100 over 3 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on PRAX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier PRAX move explainers: 2026-11-10 · 2026-11-09 · 2026-08-17 · 2026-08-07 · 2026-08-06